Executive Director, Expanded Access and Phase 4 Clinical Strategy

Mind Medicine(27 days ago)

HybridFull TimeDirector$248,140 - $296,656Clinical Development

About this role

The Executive Director, Expanded Access & Phase 4 Clinical Strategy will lead the end-to-end strategy, design, and execution of Expanded Access Programs and Phase 4 studies across MindMed’s portfolio. This role ensures programs are scientifically sound, operationally feasible, regulator-ready, and aligned with asset lifecycle, real-world evidence generation, and post-approval commitments. The position requires strategic leadership combined with hands-on execution and cross-functional collaboration across clinical, regulatory, medical affairs, and commercial teams.

View Original Listing

Required Skills

Strategic Leadership
Protocol Development
Safety Oversight
Regulatory Interactions
Cross-Functional
Stakeholder Engagement
Clinical Development
Lifecycle Management
RWE Generation
Study Design

+5 more

Qualifications

Doctoral Degree (MD, PhD, PharmD, PsyD)
10+ Years Clinical Development Experience

About Mind Medicine

mindmed.co

MindMed is a clinical-stage biopharmaceutical company that discovers, develops, and deploys psychedelic‑inspired medicines and other novel compounds to treat brain health disorders. It focuses on unmet needs across psychiatry, addiction, pain, and neurology, advancing product candidates through clinical research to improve health, promote wellness, and alleviate suffering. MindMed aims to translate emerging psychedelic science into scalable therapeutic programs and treatments.